ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas

Abstract In type 1 endometrial cancer, unopposed estrogen stimulation is thought to lead to endometrial hyperplasia which precedes malignant progression. Recent data from our group and others suggest that ALDH activity mediates stemness in endometrial cancer, but while aldehyde dehydrogenase 1 (ALDH...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vei Mah, Yahya Elshimali, Alison Chu, Neda A. Moatamed, Jamar P. Uzzell, Jessica Tsui, Stephen Schettler, Hania Shakeri, Madhuri Wadehra
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a4999bcdf8744e5fbea3ffe78e4fe2a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a4999bcdf8744e5fbea3ffe78e4fe2a3
record_format	dspace
spelling	oai:doaj.org-article:a4999bcdf8744e5fbea3ffe78e4fe2a32021-12-02T17:52:23ZALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas10.1038/s41598-021-90570-32045-2322https://doaj.org/article/a4999bcdf8744e5fbea3ffe78e4fe2a32021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90570-3https://doaj.org/toc/2045-2322Abstract In type 1 endometrial cancer, unopposed estrogen stimulation is thought to lead to endometrial hyperplasia which precedes malignant progression. Recent data from our group and others suggest that ALDH activity mediates stemness in endometrial cancer, but while aldehyde dehydrogenase 1 (ALDH1) has been suggested as a putative cancer stem cell marker in several cancer types, its clinical and prognostic value in endometrial cancer remains debated. The aim of this study was to investigate the clinical value of ALDH1 expression in endometrial hyperplasia and to determine its ability to predict progression to endometrial cancer. Interrogation of the TCGA database revealed upregulation of several isoforms in endometrial cancer, of which the ALDH1 isoforms collectively constituted the largest group. To translate its expression, a tissue microarray was previously constructed which contained a wide sampling of benign and malignant endometrial samples. The array contained a metachronous cohort of samples from individuals who either developed or did not develop endometrial cancer. Immunohistochemical staining was used to determine the intensity and frequency of ALDH1 expression. While benign proliferative and secretory endometrium showed very low levels of ALDH1, slightly higher expression was observed within the stratum basalis. In disease progression, cytoplasmic ALDH1 expression showed a step-wise increase between endometrial hyperplasia, atypical hyperplasia, and endometrial cancer. ALDH1 was also shown to be an early predictor of EC development, suggesting that it can serve as an independent prognostic indicator of patients with endometrial hyperplasia with or without atypia who would progress to cancer (p = 0.012).Vei MahYahya ElshimaliAlison ChuNeda A. MoatamedJamar P. UzzellJessica TsuiStephen SchettlerHania ShakeriMadhuri WadehraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Vei Mah Yahya Elshimali Alison Chu Neda A. Moatamed Jamar P. Uzzell Jessica Tsui Stephen Schettler Hania Shakeri Madhuri Wadehra ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas
description	Abstract In type 1 endometrial cancer, unopposed estrogen stimulation is thought to lead to endometrial hyperplasia which precedes malignant progression. Recent data from our group and others suggest that ALDH activity mediates stemness in endometrial cancer, but while aldehyde dehydrogenase 1 (ALDH1) has been suggested as a putative cancer stem cell marker in several cancer types, its clinical and prognostic value in endometrial cancer remains debated. The aim of this study was to investigate the clinical value of ALDH1 expression in endometrial hyperplasia and to determine its ability to predict progression to endometrial cancer. Interrogation of the TCGA database revealed upregulation of several isoforms in endometrial cancer, of which the ALDH1 isoforms collectively constituted the largest group. To translate its expression, a tissue microarray was previously constructed which contained a wide sampling of benign and malignant endometrial samples. The array contained a metachronous cohort of samples from individuals who either developed or did not develop endometrial cancer. Immunohistochemical staining was used to determine the intensity and frequency of ALDH1 expression. While benign proliferative and secretory endometrium showed very low levels of ALDH1, slightly higher expression was observed within the stratum basalis. In disease progression, cytoplasmic ALDH1 expression showed a step-wise increase between endometrial hyperplasia, atypical hyperplasia, and endometrial cancer. ALDH1 was also shown to be an early predictor of EC development, suggesting that it can serve as an independent prognostic indicator of patients with endometrial hyperplasia with or without atypia who would progress to cancer (p = 0.012).
format	article
author	Vei Mah Yahya Elshimali Alison Chu Neda A. Moatamed Jamar P. Uzzell Jessica Tsui Stephen Schettler Hania Shakeri Madhuri Wadehra
author_facet	Vei Mah Yahya Elshimali Alison Chu Neda A. Moatamed Jamar P. Uzzell Jessica Tsui Stephen Schettler Hania Shakeri Madhuri Wadehra
author_sort	Vei Mah
title	ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas
title_short	ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas
title_full	ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas
title_fullStr	ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas
title_full_unstemmed	ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas
title_sort	aldh1 expression predicts progression of premalignant lesions to cancer in type i endometrial carcinomas
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a4999bcdf8744e5fbea3ffe78e4fe2a3
work_keys_str_mv	AT veimah aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT yahyaelshimali aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT alisonchu aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT nedaamoatamed aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT jamarpuzzell aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT jessicatsui aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT stephenschettler aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT haniashakeri aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas AT madhuriwadehra aldh1expressionpredictsprogressionofpremalignantlesionstocancerintypeiendometrialcarcinomas
_version_	1718379245101645824

ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas

Ejemplares similares